We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Harpoon

News List

Arix Bioscience plc: Team changes firstwordpharma
July 07, 2021
Arix Bioscience plc (“Arix” or “the Company”) (LSE: ARIX), a global venture capital company focused on investing and building breakthrough biotech companies, today announces that Mark Chin will be re-joining the Arix investment team as a Managing Director
Harpoon Therapeutics Granted Orphan Drug Designation for Multiple Myeloma Treatment americanpharmaceuticalreview
January 20, 2021
Harpoon Therapeutics announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for HPN217 for the treatment of multiple myeloma. HPN217, a tri-specific T cell activating recombinant protein construct (TriTAC®) targets ...
Harpoon and Gossamer sneak out IPOs before potential SEC shutdown pharmaphorum
February 15, 2019
Immunotherapy specialist Harpoon Therapeutics has joined a group of biotechs that have sneaked out IPOs before another potential US government shutdown this weekend that could prevent further listings.
Harpoon files $86M IPO to help fund its T-cell engager platform fiercebiotech
January 04, 2019
Fresh off raising $70 million through a series C round just over a month ago, Harpoon Therapeutics announced it will go public with an $86.25 million IPO to further support its portfolio of early-stage T-cell engagers aimed at solid tumors.....